BlackRock
NGNE icon

BlackRock’s Neurogene NGNE Stock Holding History

BlackRock’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.3M Buy
1,005,070
+59,487
+6% +$1.15M ﹤0.01% 3073
2025
Q4 		$19.5M Sell
945,583
-5,517
-0.6% -$137K ﹤0.01% 3121
2025
Q3 		$16.5M Sell
951,100
-26,582
-3% -$534K ﹤0.01% 3201
2025
Q2 		$14.6M Sell
977,682
-421,451
-30% -$6.61M ﹤0.01% 3204
2025
Q1 		$16.4M Sell
1,399,133
-117,024
-8% -$2.03M ﹤0.01% 3053
2024
Q4 		$34.7M Buy
1,516,157
+144,278
+11% +$5.37M ﹤0.01% 2693
2024
Q3 		$57.6M Sell
1,371,879
-22,835
-2% -$886K ﹤0.01% 2390
2024
Q2 		$50.8M Buy
1,394,714
+540,123
+63% +$19.1M ﹤0.01% 2398
2024
Q1 		$43.5M Buy
854,591
+830,440
+3,439% +$27.7M ﹤0.01% 2519
2023
Q4 		$468K Sell
24,151
-2
-0% -$29 ﹤0.01% 4439
2023
Q3 		$382K Sell
24,153
-44
-0.2% -$650 ﹤0.01% 4492
2023
Q2 		$402K Sell
24,197
-4,027
-14% -$66K ﹤0.01% 4546
2023
Q1 		$395K Sell
28,224
-2,473
-8% -$29K ﹤0.01% 4587
2022
Q4 		$312K Sell
30,697
-13,768
-31% -$142K ﹤0.01% 4735
2022
Q3 		$569K Sell
44,465
-1,077
-2% -$22K ﹤0.01% 4683
2022
Q2 		$938K Sell
45,542
-82,382
-64% -$2.01M ﹤0.01% 4557
2022
Q1 		$4.81M Sell
127,924
-2,308
-2% -$135K ﹤0.01% 3984
2021
Q4 		$12.6M Sell
130,232
-3,232
-2% -$394K ﹤0.01% 3534
2021
Q3 		$19.3M Buy
133,464
+1,526
+1% +$234K ﹤0.01% 3301
2021
Q2 		$24.4M Sell
131,938
-3,553
-3% -$786K ﹤0.01% 3181
2021
Q1 		$33.4M Buy
135,491
+1,245
+0.9% +$318K ﹤0.01% 2885
2020
Q4 		$37.9M Buy
134,246
+22,218
+20% +$5.43M ﹤0.01% 2645
2020
Q3 		$26.9M Buy
112,028
+2,664
+2% +$645K ﹤0.01% 2692
2020
Q2 		$36.3M Buy
109,364
+79,012
+260% +$20.6M ﹤0.01% 2437
2020
Q1 		$6.91M Buy
30,352
+29
+0.1% +$5.97K ﹤0.01% 3185
2019
Q4 		$7.47M Buy
30,323
+14,831
+96% +$1.48M ﹤0.01% 3380
2019
Q3 		$883K Buy
15,492
+19
+0.1% +$1.16K ﹤0.01% 4023
2019
Q2 		$730K Buy
15,473
+28
+0.2% +$1.44K ﹤0.01% 4107
2019
Q1 		$833K Sell
15,445
-127
-0.8% -$6.42K ﹤0.01% 3970
2018
Q4 		$673K Buy
15,572
+179
+1% +$8.72K ﹤0.01% 4013
2018
Q3 		$902K Buy
15,393
+8
+0.1% +$472 ﹤0.01% 3986
2018
Q2 		$815K Sell
15,385
-24,660
-62% -$6.43M ﹤0.01% 3965
2018
Q1 		$11.3M Sell
40,045
-10,670
-21% -$2.95M ﹤0.01% 3068
2017
Q4 		$11.9M Sell
50,715
-17,880
-26% -$4.19M ﹤0.01% 3057
2017
Q3 		$19.5M Buy
68,595
+1,239
+2% +$356K ﹤0.01% 2824
2017
Q2 		$19M Sell
67,356
-11,416
-14% -$3.27M ﹤0.01% 2816
2017
Q1 		$26.3M Buy
78,772
+75,402
+2,237% +$26.5M ﹤0.01% 2600
2016
Q4 		$1.11M Buy
3,370
+30
+0.9% +$8.07K ﹤0.01% 1454
2016
Q3 		$892K Buy
3,340
+810
+32% +$163K ﹤0.01% 1542
2016
Q2 		$335K Hold
2,530
– – ﹤0.01% 1842
2016
Q1 		$446K Buy
2,530
+495
+24% +$96.2K ﹤0.01% 1583
2015
Q4 		$508K Sell
2,035
-340
-14% -$89.5K ﹤0.01% 1527
2015
Q3 		$668K Buy
2,375
+1,240
+109% +$286K ﹤0.01% 1424
2015
Q2 		$158K Sell
1,135
-70
-6% -$10.7K ﹤0.01% 1719
2015
Q1 		$198K Hold
1,205
– – ﹤0.01% 1679
2014
Q4 		$181K Hold
1,205
– – ﹤0.01% 1547
2014
Q3 		$161K Sell
1,205
-95
-7% -$14.5K ﹤0.01% 1578
2014
Q2 		$245K Hold
1,300
– – ﹤0.01% 1455
2014
Q1 		$331K Buy
+1,300
New +$334K ﹤0.01% 1418

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock's NGNE Position: Q1 2026 in Review

BlackRock increased its Neurogene (NGNE) stake by 6.3% in Q1 2026, buying an estimated $1.15M and bringing the position to 1,005,070 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3073.

BlackRock first reported a position in NGNE in Q1 2014 and has held it in 49 quarters since. The position peaked at $57.6M in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • BlackRock held 1,005,070 shares of Neurogene worth $20.3M as of Q1 2026.
  • BlackRock bought 59,487 Neurogene shares in Q1 2026, an estimated $1.15M.
  • Neurogene made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3073 holding.
  • BlackRock first reported a position in Neurogene in Q1 2014 and has held it in 49 quarters since.
  • BlackRock's Neurogene position peaked at $57.6M in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.